In a paper published on June 30, 2011 in the journal Nature, researchers working as part of The Cancer Genome Atlas (TCGA) Research Network report that they have created a genetic “map” of ovarian cancer. This important work, which is the largest study of any tumor type to date, will help researchers better understand the disease and will pave the way for more effective, targeted treatment.
Members of Ovarian Cancer Research Fund’s Scientific Advisory Committee, Board of Directors, as well as OCRF grantees, contributed to this landmark study.
Analyzing hundreds of samples of high grade serous ovarian cancer (the most common and deadly kind of ovarian cancer), researchers made several important findings, including:
- • There appear to be four different subtypes of high-grade serous ovarian cancer, as well as four more additional related subtypes, based on the genetic scan. While all grouped together as “ovarian cancer,” they are not in fact alike.
- • Abnormalities present in a key gene, called TP53, were found in nearly all (96%) of patients diagnosed with these tumors.
- • Just over one in every five of the tumors were found to have tumor mutations in the BRCA1 and BRCA2 genes, which have long been linked to risks for both ovarian and breast cancers. In this case, patients whose cancers carried these mutations had better survival rates than those who did not.
- • Overall, specific patterns in 108 genes were also linked to poorer survival, while those for another 85 genes were linked to better outcomes. Patients with genetic activity deemed “poor” were found to have 23 percent shorter survival than those without such genetic aberrations.
The genomic scan also points to new leads for potential treatments. For example, mapping also revealed 68 genes that could become appropriate therapeutic targets for medications — either drugs already approved for cancer treatment by the FDA or drugs still under development, the researchers noted.
Dr. Andrew Berchuck of Duke University, who contributed to the research and who serves on OCRF’s Scientific Advisory Committee, said that the main point here is that “not all ovarian cancers are alike.”
“This was suspected to be the case,” said Berchuck, but, “no one’s ever mapped it out in extraordinary detail like this before, so that we can begin to understand the biology and root causes of what’s going on,” he pointed out.
“For patients, what’s important is that we can now look at an individual cancer and characterize the molecular alterations that have caused that specific cancer to arise,” Berchuck said. “And then those alterations become therapeutic targets for treating that particular cancer. So it really ushers in the potential for personalized medicine, in which you’re not treating all ovarian cancers in the same way. Of course, it’s a big leap between that knowledge and being able to do something about it. But this represents a major step in the right direction.”